Biofrontera Stock Rises After Allowance for U.S. Patent on Innovative Illumination Protocol
Dec 2, 2021 By MarketDepth
Biofrontera Inc. (NASDAQ: BFRI) shares spiked more than 35% after the biopharmaceutical company announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent application number 17/234,490, titled “Illumination for Photodynamic Therapy,” that covers an innovative, pain-reducing illumination protocol for photodynamic therapy (PDT).
“This patented illumination protocol demonstrates Biofrontera’s commitment to the patients’ need for innovative treatments. The patent also strengthens Biofrontera’s competitiveness for our FDA-approved combination product, Ameluz® together with our PDT-lamp BF-RhodoLED® and its successor model RhodoLED® XL in the U.S. by providing an opportunity to pursue label expansion to include more patient-friendly protocols.”
Erica Monaco, Chief Executive Officer of Biofrontera Inc.
The patent application claims a method for photodynamic therapy in which a dynamic and innovative illumination protocol is implemented. This protocol consists of changing illumination intensities combined in a predefined order with interruptions of the illumination to specifically modulate and reduce pain perception to the patient. The new illumination protocol aims at combining the high efficacy of Ameluz® with the flexibility of BF-RhodoLED® to modulate light for pain reduction to ultimately become a new standard-of-care in PDT.
Therapies for Skin Diseases
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer.
